OA12456A - Pregabalin lactose conjugates. - Google Patents
Pregabalin lactose conjugates. Download PDFInfo
- Publication number
- OA12456A OA12456A OA1200300232A OA1200300232A OA12456A OA 12456 A OA12456 A OA 12456A OA 1200300232 A OA1200300232 A OA 1200300232A OA 1200300232 A OA1200300232 A OA 1200300232A OA 12456 A OA12456 A OA 12456A
- Authority
- OA
- OAPI
- Prior art keywords
- tetrahydro
- pyran
- isobutyl
- pyrrolidin
- hydroxymethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28017601P | 2001-03-30 | 2001-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA12456A true OA12456A (en) | 2004-08-24 |
Family
ID=23072002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200300232A OA12456A (en) | 2001-03-30 | 2002-02-25 | Pregabalin lactose conjugates. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US7022678B2 (es) |
| EP (1) | EP1377318A2 (es) |
| JP (1) | JP2004524357A (es) |
| KR (1) | KR20040008146A (es) |
| CN (1) | CN1511043A (es) |
| AP (1) | AP2003002873A0 (es) |
| AR (1) | AR033024A1 (es) |
| BG (1) | BG108193A (es) |
| BR (1) | BR0208439A (es) |
| CA (1) | CA2440468C (es) |
| CZ (1) | CZ20032547A3 (es) |
| DO (1) | DOP2002000356A (es) |
| EA (1) | EA200300954A1 (es) |
| EC (1) | ECSP034740A (es) |
| EE (1) | EE200300480A (es) |
| GT (1) | GT200200051A (es) |
| HU (1) | HUP0303956A2 (es) |
| IL (1) | IL157879A0 (es) |
| IS (1) | IS6912A (es) |
| MA (1) | MA27004A1 (es) |
| MX (1) | MXPA03007437A (es) |
| NO (1) | NO20034348L (es) |
| OA (1) | OA12456A (es) |
| PA (1) | PA8542101A1 (es) |
| PE (1) | PE20021016A1 (es) |
| PL (1) | PL369179A1 (es) |
| SK (1) | SK11832003A3 (es) |
| SV (1) | SV2003000928A (es) |
| TN (1) | TNSN02038A1 (es) |
| UY (1) | UY27233A1 (es) |
| WO (1) | WO2002078747A2 (es) |
| ZA (1) | ZA200306608B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9710536A (pt) | 1996-07-24 | 1999-08-17 | Warner Lambert Co | Isobutilgaba e seus derivados para o tratamento da dor |
| WO2007035890A1 (en) | 2005-09-19 | 2007-03-29 | Teva Pharmaceutical Industries Ltd. | An asymmetric synthesis of ( s ) - ( + ) -3- (aminomethyl) -5-methylhexanoic acid |
| DE102007019071A1 (de) | 2007-04-23 | 2008-10-30 | Ratiopharm Gmbh | Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin |
| SG176464A1 (en) | 2008-05-09 | 2011-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| KR20100107500A (ko) * | 2008-06-23 | 2010-10-05 | 테바 파마슈티컬 인더스트리즈 리미티드 | (ｓ) 또는 (ｒ)-이소-부틸-글루타릭 에스테르의 입체선택적 효소 합성방법 |
| WO2010115612A2 (en) | 2009-04-10 | 2010-10-14 | Synthon B.V. | Pregabalin compositions |
| WO2010150221A1 (en) | 2009-06-25 | 2010-12-29 | Wockhardt Research Centre | Taste masked pharmaceutical compositions of pregabalin |
| HU230031B1 (hu) | 2010-03-01 | 2015-05-28 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény |
| CN103494796B (zh) * | 2013-09-30 | 2016-01-20 | 浙江华义医药有限公司 | 普瑞巴林稳定的药物组合物及其制备方法 |
| CN104311608B (zh) * | 2014-10-28 | 2016-10-05 | 河南中烟工业有限责任公司 | 亲水型烟草增香保润剂Mal-Hyp、制备方法及其应用 |
| CN104370986B (zh) * | 2014-10-28 | 2017-07-04 | 河南中烟工业有限责任公司 | 糖衍生物烟用增香保润剂Mal‑Pro、制备方法及其应用 |
| CN105520918B (zh) * | 2015-12-31 | 2018-12-11 | 常州市阳光药业有限公司 | 普瑞巴林胶囊 |
| CN105434395B (zh) * | 2015-12-31 | 2018-12-11 | 常州市阳光药业有限公司 | 普瑞巴林胶囊及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| FR2781793B1 (fr) * | 1998-08-03 | 2001-07-20 | Prographarm Lab | Procede de fabrication de granules de gabapentine enrobes |
| WO2000023067A1 (en) * | 1998-10-16 | 2000-04-27 | Warner-Lambert Company | Method for the treatment of mania and bipolar disorder |
| EP1337271B1 (en) * | 2000-11-30 | 2004-11-03 | Pfizer Products Inc. | Combination of gaba agonists and sorbitol dehydrogenase inhibitors |
-
2002
- 2002-01-28 US US10/058,903 patent/US7022678B2/en not_active Expired - Fee Related
- 2002-02-25 CN CNA028067509A patent/CN1511043A/zh active Pending
- 2002-02-25 BR BR0208439-2A patent/BR0208439A/pt not_active IP Right Cessation
- 2002-02-25 KR KR10-2003-7012714A patent/KR20040008146A/ko not_active Application Discontinuation
- 2002-02-25 SK SK1183-2003A patent/SK11832003A3/sk not_active Application Discontinuation
- 2002-02-25 EA EA200300954A patent/EA200300954A1/ru unknown
- 2002-02-25 MX MXPA03007437A patent/MXPA03007437A/es active IP Right Grant
- 2002-02-25 EE EEP200300480A patent/EE200300480A/xx unknown
- 2002-02-25 OA OA1200300232A patent/OA12456A/en unknown
- 2002-02-25 WO PCT/IB2002/000647 patent/WO2002078747A2/en active Application Filing
- 2002-02-25 PL PL02369179A patent/PL369179A1/xx not_active Application Discontinuation
- 2002-02-25 CZ CZ20032547A patent/CZ20032547A3/cs unknown
- 2002-02-25 CA CA002440468A patent/CA2440468C/en not_active Expired - Fee Related
- 2002-02-25 HU HU0303956A patent/HUP0303956A2/hu unknown
- 2002-02-25 EP EP02702614A patent/EP1377318A2/en not_active Withdrawn
- 2002-02-25 IL IL15787902A patent/IL157879A0/xx unknown
- 2002-02-25 JP JP2002577011A patent/JP2004524357A/ja active Pending
- 2002-02-25 AP APAP/P/2003/002873A patent/AP2003002873A0/en unknown
- 2002-03-07 DO DO2002000356A patent/DOP2002000356A/es unknown
- 2002-03-19 GT GT200200051A patent/GT200200051A/es unknown
- 2002-03-22 SV SV2002000928A patent/SV2003000928A/es not_active Application Discontinuation
- 2002-03-27 PE PE2002000252A patent/PE20021016A1/es not_active Application Discontinuation
- 2002-03-27 PA PA20028542101A patent/PA8542101A1/es unknown
- 2002-03-27 AR ARP020101140A patent/AR033024A1/es unknown
- 2002-03-27 UY UY27233A patent/UY27233A1/es not_active Application Discontinuation
- 2002-03-29 TN TNTNSN02038A patent/TNSN02038A1/fr unknown
-
2003
- 2003-08-14 IS IS6912A patent/IS6912A/is unknown
- 2003-08-21 EC EC2003004740A patent/ECSP034740A/es unknown
- 2003-08-25 ZA ZA200306608A patent/ZA200306608B/en unknown
- 2003-09-17 MA MA27315A patent/MA27004A1/fr unknown
- 2003-09-24 BG BG108193A patent/BG108193A/xx unknown
- 2003-09-29 NO NO20034348A patent/NO20034348L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| OA12456A (en) | Pregabalin lactose conjugates. | |
| EP3369738B1 (en) | Method for making nicotinoyl ribosides and nicotinamide beta-riboside | |
| DE60005017T2 (de) | Prodrugs von impdh-inhibierenden carbamaten | |
| US8703755B2 (en) | Analogs of benzoquinone-containing ansamycins and methods of use thereof | |
| TW581677B (en) | Use of alkylated iminosugars to treat multidrug resistance | |
| CN103781472A (zh) | 丙泊酚苷衍生物的合成和使用 | |
| US20220000814A1 (en) | Methods for treatment of prader-willi syndrome | |
| EP0381070A1 (en) | Synthetic amphiphilic glycoconjugates for neurological use | |
| US7786168B2 (en) | Phenolic acid salts of gabapentin in solid dosage forms and methods of use | |
| CN112004799A (zh) | Akr1c3抑制剂及医药用途 | |
| JP2022510480A (ja) | ドーパミン応答性障害の治療のための糖にコンジュゲートされたｌ－ｄｏｐａ及び／またはｄｏｐａデカルボキシラーゼ阻害剤 | |
| AU2002236134A1 (en) | Pregabalin lactose conjugates | |
| EP1064294B1 (en) | 5-imino-13-deoxy anthracycline derivatives, their uses, and processes for preparing them | |
| US4942226A (en) | Halogenated pyrimidine nucleosides and their derivatives | |
| CN112174865A (zh) | Akr1c3抑制剂及医药用途 | |
| KR20210013081A (ko) | 나프록센 및 프레가발린의 1-(아실옥시)-알킬 카르바메이트 약물 복합체의 결정형 | |
| CN1270522A (zh) | 13－脱氧蒽环类抗生素衍生物及其制备方法 | |
| US20240148751A1 (en) | Identification of oleanolic acid and plant extract for glucose-6-phosphate dehydrogenase-related disorders including Bag3opathy | |
| CA2070124A1 (en) | Uses of a ganglioside derivative | |
| KR20210008223A (ko) | 탈모증의 치료 또는 개선을 위한 화합물 및 이들의 용도 | |
| EP3988559A1 (en) | 2-benzylidene hydrazinoadenosine compounds having a2a adenosine receptor agnostic activity | |
| TW202136201A (zh) | Ａｋｒ１ｃ３抑制劑及醫藥用途 | |
| EP3492071A1 (en) | Pharmaceutical composition comprising benzocaine with enhanced stability |